P/S-Lipoprotein(a)
Senast reviderad:
Sakkunnig:Anders Kallner
- Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9. Journal of the American Medical Association
- Mach F, Baigent C, Catapano CL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111-188. pmid:31591002 PubMed
- Theodorsson E, Berggren Söderlund M, (red). Laurells Klinisk kemi i praktisk medicin. Lund: Studentlitteratur, 2018
- Kamstrup PR. Lipoprotein(a) and ischemic heart disease--a causal association? A review. Atherosclerosis 2010; 211: 15-23. PubMed
- Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53. European Heart Journal
- Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423. Journal of the American Medical Association
- Trinder M, Paruchuri K, Haidermota S, et al. Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J Am Coll Cardiol 2022. pmid:35177190 PubMed
- Anders Kallner, docent och fd överläkare, Karolinska universitetslaboratoriet, Karolinska universitetssjukhuset
- Remy Waardenburg, specialist i allmänmedicin, medicinsk redaktör Medibas